Abstract
Precision medicine, also known as personalized medicine, is concerned with finding the right treatment for the right patient at the right time. It is a way of thinking focused on parsing heterogeneity ultimately down to the level of the individual. Its main mission is to identify characteristics of heterogeneous clinical conditions so as to target tailored therapies to individuals. Precision Medicine however is not an agnostic collection of all manner of clinical, genetic and other biologic data in select cohorts. This is an important point. Simply collecting as much information as possible on individuals without applying this way of thinking should not be considered Precision Medicine.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Livingston G, Sommerlad A, Orgeta V et al (2017) Dementia prevention, intervention, and care. Lancet 390(10113):2673–2734. https://doi.org/10.1016/s0140-6736(17)31363-6
BMJ (2021) Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis Sarah F AckleyScott C ZimmermanWilla D BrenowitzEric J Tchetgen TchetgenAudra L GoldJennifer J ManlyElizabeth Rose MayedaTeresa J FilshteinMelinda C PowerFanny M ElahiAdam M BrickmanM Maria Glymour https://doi.org/10.1136/bmj.n156
Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos J-M (2019) Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer’s Coordinating Centers volunteers. Alzheimers Dement Diagn Assess Dis Monit 11(1):333–339. https://doi.org/10.1016/j.dadm.2019.02.006
Oh ES, Blennow K, Bigelow GE et al (2018) Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia. Reddy H, ed. PLoS One 13(9):e0204695–e0204610. https://doi.org/10.1371/journal.pone.0204695
Dourlen P, Kilinc D, Malmanche N, Chapuis J, Lambert J-C (2019) The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol:1–16. https://doi.org/10.1007/s00401-019-02004-0
Jia L, Qiu Q, Zhang H et al (2019) Concordance between the assessment of Aβ42, T-tau, and P-T181- tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement 15(8):1071–1080. https://doi.org/10.1016/j.jalz.2019.05.002
O’Bryant SE, Zhang F, Johnson LA et al (2018) A precision medicine model for targeted NSAID therapy in Alzheimer’s disease. J Alzheimers Dis 66(1):97–104. https://doi.org/10.3233/jad-180619
Samus QM, Johnston D, Black BS et al (2014) A multidimensional home-based care coordination intervention for elders with memory disorders: the maximizing Independence at home (MIND) pilot randomized trial. Am J Geriatr Psychiatry 3:1–16. https://doi.org/10.1016/j.jagp.2013.12.175
Acknowledgments
We are grateful to the many supporters of the Richman Center and to Jiaxin Li for the development of Fig. 5. Dr. Kapogiannis’ effort is supported in part by the Intramural Research Program, National Institute on Aging (NIA/NIH).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Avramopoulos, D. et al. (2021). Developing Treatments for Alzheimer’s and Related Disorders with Precision Medicine: A Vision. In: Vlamos, P. (eds) GeNeDis 2020. Advances in Experimental Medicine and Biology, vol 1339. Springer, Cham. https://doi.org/10.1007/978-3-030-78787-5_49
Download citation
DOI: https://doi.org/10.1007/978-3-030-78787-5_49
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-78786-8
Online ISBN: 978-3-030-78787-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)